Ali Uğur Ergi̇n
Research Subjects
Ali Uğur Ergi̇n has a total of 4 co-authors. Here are the top co-authors by number of shared publications:
- Düriye Sıla Karagöz Özen
SAMSUN ÜNİVERSİTESİ, SÜREKLİ EĞİTİM UYGULAMA VE ARAŞTIRMA MERKEZİ
2 shared publications - Mehmet Derya Demirağ
Department of Rheumatology, School of Medicine, Samsun University , Samsun
2 shared publications - Elif Dağistan Ergi̇n
SAMSUN ÜNİVERSİTESİ, SÜREKLİ EĞİTİM UYGULAMA VE ARAŞTIRMA MERKEZİ
1 shared publication - Orhan Demir
Department of Endocrinology and Metabolism, Gulhane School of Medicine, University of Health Sciences, Ankara, Türkiye
1 shared publication
Latest Publications
- 1 March 2024
- Published by Ordu University in Black Sea Journal of Health Science
- Vol. 7 (2) , 73-79
Evaluation of Colorectal Cancer Screening Awareness and Compliance Rates over the Age of 40: Single Center Data in Türkiye
The frequency of colorectal cancer is increasing under the age of 50, and new sights have emerged regarding the initiation of screening in the earlier age group. This study aims to measure the consciousness of patients over the age of 40 about colorectal cancer screening and to reveal the screening rates of individuals over the age of 50. 300 consecutive patients who applied to our center and were older than 40 years of age were included. The questionnaire was created based on current guidelines and literature knowledge by the investigators and done through face-to-face interviews. Patients over 50 years of age who did not undergo screening were analyzed by dividing them into groups according to their socio-demographic characteristics and colorectal cancer risk factors. While 64.7% of the participants stated that they knew about colorectal cancer screening, only 32.4% of the participants aged 50 and over had colorectal cancer screening. The vast majority of patients stated that they did not have enough knowledge about the subject. The rate of participants who stated that they were considering entering the cancer screening program after completing this questionnaire was 73.7%. Colorectal cancer screening rates of non-smokers, women, and married participants were higher than the other group (P=0.016, P=0.017, and P=0.033, respectively). This study shows low screening compliance of individuals over the age of 50. We think that it is important to encourage and inform all adults over the age of 40 about colorectal cancer screening for public health.
- 1 March 2024
- Published by Ordu University in Black Sea Journal of Health Science
- Vol. 7 (2) , 73-79
Evaluation of Colorectal Cancer Screening Awareness and Compliance Rates over the Age of 40: Single Center Data in Türkiye
The frequency of colorectal cancer is increasing under the age of 50, and new sights have emerged regarding the initiation of screening in the earlier age group. This study aims to measure the consciousness of patients over the age of 40 about colorectal cancer screening and to reveal the screening rates of individuals over the age of 50. 300 consecutive patients who applied to our center and were older than 40 years of age were included. The questionnaire was created based on current guidelines and literature knowledge by the investigators and done through face-to-face interviews. Patients over 50 years of age who did not undergo screening were analyzed by dividing them into groups according to their socio-demographic characteristics and colorectal cancer risk factors. While 64.7% of the participants stated that they knew about colorectal cancer screening, only 32.4% of the participants aged 50 and over had colorectal cancer screening. The vast majority of patients stated that they did not have enough knowledge about the subject. The rate of participants who stated that they were considering entering the cancer screening program after completing this questionnaire was 73.7%. Colorectal cancer screening rates of non-smokers, women, and married participants were higher than the other group (P=0.016, P=0.017, and P=0.033, respectively). This study shows low screening compliance of individuals over the age of 50. We think that it is important to encourage and inform all adults over the age of 40 about colorectal cancer screening for public health.
- Open Access
- 8 December 2022
- Published by MediHealth Academy in Kastamonu Medical Journal
- Vol. 2 (4) , 135-137
A case of type 1 Diabetes mellitus unresponsive to insulin glulisine
A 29-year-old man applied to the internal medicine outpatient clinic with fatigue and high plasma glucose levels. He had type 1 Diabetes Mellitus for 10 years and was using insulin glargine U300 and insulin glulisine for treatment. His glycosylated hemoglobin level was 16.7%, and he was hospitalized. Insulin doses were calculated as 1 unite/kg /day; glulisine 3x8 unit/day and glargine U300 1x18 unit/day were ordered. Although we increased the total insulin dosage to 1,5 units/kg/day, the plasma glucose measurements did not improve. The short-acting insulin analog was switched to insulin aspart based on the fact that insulin autoantibodies might cause this situation. On aspart treatment, the patient suffered from hypoglycemia with the same doses of glulisine. The occurrence of insulin autoantibodies against glulisine was confirmed clinically. Basal insulin dose was reduced to 20 units, and aspart 3x6 units/day was enough for plasma glucose control. Hyperglycemia due to autoantibodies against analog insulins is very rare. Here we report a type 1 Diabetes Mellitus patient who was on glulisine treatment for 10 years, and whose blood glucose measurements deteriorated recently. Hyperglycemia was regulated after the insulin switch from glulisine to aspart. This rare case report must be kept in mind in hyperglycemic patients with a history of long-time analog insulin treatment.
- 8 December 2022
- Published by MediHealth Academy in Kastamonu Medical Journal
- Vol. 2 (4) , 135-137
Open AccessA case of type 1 Diabetes mellitus unresponsive to insulin glulisine
A 29-year-old man applied to the internal medicine outpatient clinic with fatigue and high plasma glucose levels. He had type 1 Diabetes Mellitus for 10 years and was using insulin glargine U300 and insulin glulisine for treatment. His glycosylated hemoglobin level was 16.7%, and he was hospitalized. Insulin doses were calculated as 1 unite/kg /day; glulisine 3x8 unit/day and glargine U300 1x18 unit/day were ordered. Although we increased the total insulin dosage to 1,5 units/kg/day, the plasma glucose measurements did not improve. The short-acting insulin analog was switched to insulin aspart based on the fact that insulin autoantibodies might cause this situation. On aspart treatment, the patient suffered from hypoglycemia with the same doses of glulisine. The occurrence of insulin autoantibodies against glulisine was confirmed clinically. Basal insulin dose was reduced to 20 units, and aspart 3x6 units/day was enough for plasma glucose control. Hyperglycemia due to autoantibodies against analog insulins is very rare. Here we report a type 1 Diabetes Mellitus patient who was on glulisine treatment for 10 years, and whose blood glucose measurements deteriorated recently. Hyperglycemia was regulated after the insulin switch from glulisine to aspart. This rare case report must be kept in mind in hyperglycemic patients with a history of long-time analog insulin treatment.